We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Subsidiary Hit With Patent Infringement Ruling for ADHD Drug
Teva Subsidiary Hit With Patent Infringement Ruling for ADHD Drug
Teva Pharmaceuticals subsidiary Actavis Laboratories infringed upon five patents belonging to Tris Pharma by producing and marketing generic versions of Tris’s Quillivant XR, an extended-release liquid formulation of methylphenidate to treat attention deficit hyperactive disorder (ADHD), a federal court has ruled.